Fibrogen Company Profile: FGEN Business, Executives & Facts

Current data has a 15-minute delay. Please / to get real-time quotes.

Summary

Options

Financials

News

Filings

Profile

Key StatisticsCurrency:USD

EPS(TTM)

-1.23

P/E(TTM)

-0.94

BVPS

-1.82

P/B

-0.24

Revenue(2024 Q4)

-123.26M

YoY

-66.99%

Net Income(2024 Q4)

17.98M

YoY

131.98%

Gross Margin(TTM)

47.47%

Net Margin(TTM)

-160.63%

ROE(TTM)

Debt ratio

185.60%

Dividend Yield(TTM)

Payout Ratio

Profile

Fibrogen, Inc.

 A biopharmaceutical company that developing novel therapeutic agents to treat anemia, fibrotic disease, and cancer 

Fibrogen, Inc., was incorporated in Delaware in 1993. FibroGen is a biopharmaceutical company dedicated to the discovery, development and commercialization of a range of best-in-class therapies. The company uses its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia inducible factor (HIF) to drive the unmet need for innovative drug treatments. Pamrevlumab is a human monoclonal antibody against CTGF for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), metastatic pancreatic cancer and Duchenne muscular dystrophy (DMD). Roxadustat (EVRENZOTM) is currently approved for the treatment of anemia in dialysis and non-dialysis CKD patients in China, Europe, Japan and many oth…More

Related Sections

B
Biotechnology+1.37%

Pharma Tracker

No Upcoming Event

Stay ahead with our Pharma Tracker: Monitor the latest developments in new drug research, financial health, and FDA updates for the company

Revenue BreakdownCurrency:USD

Data source:2024 FY

Total

29.62M

Name

Revenue

Proportion

Development and Other

1.95M

6.58%

Drug Product

27.67M

93.42%

Major shareholders

Fidelity Management & Research

The Vanguard Group

BlackRock

Astellas Pharma

Thomas B. Neff

DividendsCurrency:USD

No Data

Net Income Attributable to Parent

Total Cash Dividends

Payout Ratio

Institutional Holdings

Totally

institutions reported their ownerships on

FGEN

Institutional Holding Ratio

Price

Insider Transactions

Net increase

Net decrease

Price

Executive Profile

Feedback

Disclaimer: All data and information presented above are from third-party data sources. They are for reference only and do not constitute any investment advice.

Market Data Risk Disclosure|Privacy Policy

You Can Understand Stocks with AI.

Why NVDA surged 16.40%?

Because it

AInvest

Aime Coplilot

Invest Smarter With AI Power.

Open App